水飞蓟宾磷脂复合物治疗慢性乙型肝炎34例

目的:观察水飞蓟宾磷脂复合物治疗肝功能异常的慢性乙型肝炎的疗效和安全性.方法:选取68例肝功能异常的慢性乙肝患者,随机分成对照组和治疗组各34例,对照组给予口服肌苷片1 200mg·d-1治疗,试验组在此基础上加用口服水飞蓟宾磷脂复合物360mg·d-1,共12周,对两组进行比较,评价治疗前后患者临床症状和肝功恢复情况,同时记录不良反应.结果:治疗组有效率达79.4%,对照组为32.3%,两组比较差异有显著性,且无明显的不良反应.结论:水飞蓟宾磷脂复合物治疗慢性乙肝患者的肝功能异常安全、有效.

Treatment of chronic hepatitis B with silibinin capsules

Objective:To evaluate the efficacy of silibinin capsules for patients with chronic hep- atitis B (CHB). Methods: Sixty-eight patients with chronic hepatitis (abnormal ALT level) were equally randomized to receive either silibinin capsules (360mg) plus inosine (1200mg) daily or inosine monotherapy (1200mg) daily for 12 weeks. The primary endpoints were to monitor the improvement of abnormal ALT and AST in weeks 4,8 and 12 after the administration of the study drugs. Results:79.4 percent of patients treated with silibinin plus inosine experienced an ALT and AST normalization, compared to 32.3 percent of patients treated with inosine alone (P>0.05). No serious adverse events were reported in the bicombination group in the course of the therapy. Conclusion: Addition of silibinin capsules to inosine regimen achieves a significant normalizatoin of the ALT and AST levels in patients with CHB.